XBiotech launches Phase II clinical trial evaluating Vilamakitug for active axial spondyloarthritis. Phase II trial start advances pipeline with potential to drive future revenue and investor sentiment.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | 2.10 |
—
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 200.02 | 172.68 | 125.55 | 109.53 |
| Receivables | 0.94 | 0.86 | 0.36 | 0.29 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 201.72 | 174.57 | 126.95 | 111.16 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.52 | 2.22 | 1.54 | 1.11 |
| ST’ Debt | — | 10.25 | — | — |
| Other | — | — | — | — |
| 6.10 | 15.11 | 7.93 | 3.35 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’22 | 0.50 | 1.53 | 1.68 | 0.30 |
4.01
|
| ’21 | 4.85 | 4.53 | 4.52 | 4.50 |
18.39
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (8.97) | (4.51) | — | — |
—
|
| ’25 | (6.72) | (5.99) | (4.26) | (22.95) |
(39.92)
|
| ’24 | (7.20) | (11.38) | (5.84) | (6.54) |
(30.96)
|
| ’23 | (4.81) | (9.00) | (1.49) | (3.43) |
(18.72)
|
| ’22 | (5.12) | (5.39) | (1.15) | (3.16) |
(14.82)
|
| ’21 | 1.81 | 72.80 | (3.40) | (1.76) |
69.45
|
| ’20 | (60.67) | (11.57) | 7.48 | (0.39) |
(65.15)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (8.97) | (4.51) | — | — |
—
|
| ’25 | (6.81) | (6.04) | (4.37) | (22.99) |
(40.21)
|
| ’24 | (7.46) | (12.00) | (6.18) | (6.62) |
(32.27)
|
| ’23 | (4.81) | (9.20) | (1.52) | (3.55) |
(19.09)
|
| ’22 | (5.28) | (5.47) | (1.36) | (3.30) |
(15.41)
|
| ’21 | 1.17 | 71.09 | (4.10) | (2.23) |
65.92
|
| ’20 | (61.06) | (11.99) | 6.79 | (2.61) |
(68.88)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.18) | (0.22) | — | — |
—
|
| ’25 | (0.36) | (0.06) | (0.20) | (0.88) |
(1.49)
|
| ’24 | (0.33) | (0.43) | (0.16) | (0.34) |
(1.26)
|
| ’23 | (0.13) | (0.29) | (0.24) | (0.16) |
(0.81)
|
| ’22 | (0.18) | (0.38) | (0.42) | (0.10) |
(1.08)
|
| ’21 | (0.09) | (0.17) | (0.11) | (0.21) |
(0.58)
|
| ’20 | 0.00 | (0.24) | (0.09) | (0.06) |
(0.36)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 3.00 | 3.05 | 3.51 | 2.09 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 11.90 | 6.69 | 9.96 | 4.67 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 85 | 82 | 92 | 85 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.05 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.01 | — | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 83.77% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.59) | (24.31) | (38.56) | (45.30) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (837.61%) | 0.00% | 0.00% | 0.00% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (32.90) | (24.56) | (38.53) | (45.54) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.61 | 1.74 | 1.75 | 1.69 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.13 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.08) | (0.81) | (1.26) | (1.49) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.49) | (0.62) | (1.02) | (1.31) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.02) | (0.01) | (0.04) | (0.01) | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.51) | (0.63) | (1.06) | (1.32) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.90 | 7.19 | 5.98 | 4.60 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 30.44 | 30.44 | 30.46 | 30.49 | — | — | — |
Shares
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | — | — | — | — | — | — |
PE Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.66 | — | — | — | — | — | — |
PS Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.43 | — | — | — | — | — | — |
PB Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (28.58) | — | — | — | — | — | — |
EV/Sales
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.44 | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.82) | (18.72) | (30.96) | (39.92) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.58) | (0.36) | (1.30) | (0.29) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (15.41) | (19.09) | (32.27) | (40.21) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 215.78 | 195.62 | 159.46 | 119.02 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | — | — | 10.25 | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (217.48) | (200.02) | (162.43) | (125.55) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 240.40 | 218.85 | 182.27 | 140.35 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.62%) | (10.39%) | (18.10%) | (26.08%) | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (94.03%) | (124.55%) | (133.79%) | (235.17%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.91%) | (10.69%) | (19.21%) | (28.23%) | — | — | — |
ROE
|
XBiotech Inc. (XBIT) embodies the biotech rollercoaster, trading at rock-bottom levels that scream pessimism despite analysts’ eye-popping 635% upside to consensus targets. From a $26 peak in 2020 fueled by initial Xilonex revenues and the transformative 2019 Novartis deal netting over $700 million, shares have cratered 85%+ amid trial setbacks, revenue evaporation, and persistent cash burn—book value per share down 69% to $5.98, with losses per share ballooning 250%. This isn’t steady growth; it’s milestone mania, where highs crash into lows as operational inefficiencies expose the fragility of small-cap biotechs.
Revenue tells a brutal boom-bust tale: $44 million in 2020 spiking to 84% gross margins, then a 90%+ plunge to near-zero by 2024, dragging ROE from 168% positive to -19% and free cash flow per share negative at -$1.06. Yet a fortress balance sheet shines through—$159 million working capital, net cash of $162 million buying 2-3 years’ runway without dilution. Insider silence adds no conviction, leaving sentiment in the doldrums.
Analysts bet big on pipeline pivots like bermekimab-Keytruda combos in colorectal cancer, with Phase 2 promise echoing Novartis glory—but history warns of HS-adjacent flops and post-deal fades. Contrarian eyes see asymmetric upside if trials deliver, but unappreciated risks like 15-20% annual book erosion or binary failures could halve shares further. A high-beta recovery gamble demanding milestone vigilance.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.